Intrexon Corp. (XON) Receives $43.78 Average PT from Brokerages
Shares of Intrexon Corp. (NYSE:XON) have been assigned a consensus rating of “Buy” from the eight brokerages that are currently covering the firm. Three research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $43.78.
A number of research firms recently weighed in on XON. Griffin Securities restated a “buy” rating and issued a $55.00 target price on shares of Intrexon Corp. in a report on Tuesday, August 16th. Zacks Investment Research lowered shares of Intrexon Corp. from a “buy” rating to a “hold” rating in a report on Friday, August 12th. Vetr upgraded shares of Intrexon Corp. from a “hold” rating to a “strong-buy” rating and set a $33.69 price objective for the company in a research note on Wednesday, August 3rd. Wunderlich reiterated a “buy” rating and issued a $50.00 price objective on shares of Intrexon Corp. in a research note on Thursday, July 7th. Finally, JMP Securities reiterated a “buy” rating on shares of Intrexon Corp. in a research note on Sunday, July 17th.
Shares of Intrexon Corp. (NYSE:XON) opened at 27.56 on Monday. Intrexon Corp. has a 52 week low of $18.52 and a 52 week high of $43.76. The company’s market capitalization is $3.26 billion. The company has a 50 day moving average price of $27.31 and a 200 day moving average price of $27.92.
Intrexon Corp. (NYSE:XON) last posted its earnings results on Tuesday, August 9th. The company reported ($0.42) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.26) by $0.16. Intrexon Corp. had a negative return on equity of 19.00% and a negative net margin of 96.65%. The business earned $52.50 million during the quarter, compared to analyst estimates of $53.78 million. During the same quarter in the prior year, the company earned ($0.37) EPS. The company’s revenue was up 17.0% on a year-over-year basis. On average, equities research analysts expect that Intrexon Corp. will post ($1.36) earnings per share for the current year.
In related news, SVP Nir Nimrodi purchased 4,000 shares of the firm’s stock in a transaction dated Monday, August 29th. The stock was bought at an average price of $26.12 per share, for a total transaction of $104,480.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 55.10% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Metropolitan Life Insurance Co. NY increased its position in Intrexon Corp. by 13.7% in the second quarter. Metropolitan Life Insurance Co. NY now owns 4,161 shares of the company’s stock valued at $102,000 after buying an additional 501 shares during the period. Advisory Services Network LLC increased its position in Intrexon Corp. by 34.3% in the third quarter. Advisory Services Network LLC now owns 4,193 shares of the company’s stock valued at $117,000 after buying an additional 1,070 shares during the period. Pacer Advisors Inc. acquired a new position in Intrexon Corp. during the second quarter valued at approximately $118,000. Advisor Group Inc. acquired a new position in Intrexon Corp. during the second quarter valued at approximately $123,000. Finally, Legal & General Group Plc increased its position in Intrexon Corp. by 3.4% in the first quarter. Legal & General Group Plc now owns 3,788 shares of the company’s stock valued at $128,000 after buying an additional 126 shares during the period. 84.05% of the stock is owned by institutional investors.
About Intrexon Corp.
Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.
Receive News & Ratings for Intrexon Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corp. and related companies with MarketBeat.com's FREE daily email newsletter.